Benzinga | Mar 9, 2021 09:17AM EST

4D Molecular Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of 4D-310 For Treatment Of Fabry Disease

EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:4), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease. Fabry disease is an inherited lysosomal storage disease with high unmet medical need that results from loss of function mutations in the alpha-galactosidase (AGA) enzyme.